NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free VRCA Stock Alerts $7.84 +0.23 (+3.02%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$7.54▼$7.9550-Day Range$4.74▼$7.8452-Week Range$2.86▼$7.95Volume106,916 shsAverage Volume166,209 shsMarket Capitalization$332.57 millionP/E RatioN/ADividend YieldN/APrice Target$11.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Verrica Pharmaceuticals alerts: Email Address Verrica Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside43.5% Upside$11.25 Price TargetShort InterestBearish15.09% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.33Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.59) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector146th out of 915 stocksPharmaceutical Preparations Industry49th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.09% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 28.3, which indicates bearish sentiment.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently decreased by 8.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVerrica Pharmaceuticals has received a 75.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Verrica Pharmaceuticals is -0.67. Previous Next 2.4 News and Social Media Coverage News SentimentVerrica Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VRCA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders42.60% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.59) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 16.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verrica Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Read More VRCA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRCA Stock News HeadlinesMay 9, 2024 | globenewswire.comVerrica Pharmaceuticals to Present at Upcoming Investor ConferencesMay 8, 2024 | globenewswire.comVerrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024May 9, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.May 3, 2024 | seekingalpha.comVRCA Verrica Pharmaceuticals Inc.April 19, 2024 | investing.comVerrica Pharmaceuticals Inc (VRCA)April 4, 2024 | msn.comVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare ConferenceApril 3, 2024 | finance.yahoo.comStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossApril 2, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMay 9, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 31, 2024 | msn.comVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market ProtectionMarch 28, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAMarch 27, 2024 | msn.comVerrica Pharma gains as FDA lists Ycanth in Orange BookMarch 26, 2024 | markets.businessinsider.comVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick FactsMarch 26, 2024 | globenewswire.comVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAMarch 3, 2024 | msn.comVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside ChatMarch 2, 2024 | finance.yahoo.comVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 2, 2024 | finance.yahoo.comWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?March 1, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy RatingMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market ExpansionMarch 1, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market AcceptanceFebruary 29, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 28, 2024 | benzinga.comEarnings Outlook For Verrica PharmaceuticalsFebruary 27, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare ConferenceFebruary 22, 2024 | finance.yahoo.comVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024See More Headlines Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/09/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRCA CUSIPN/A CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$11.25 High Stock Price Target$14.00 Low Stock Price Target$8.00 Potential Upside/Downside+43.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,000,000.00 Net Margins-1,307.47% Pretax Margin-1,307.47% Return on Equity-119.46% Return on Assets-70.35% Debt Debt-to-Equity Ratio2.22 Current Ratio4.55 Quick Ratio4.49 Sales & Book Value Annual Sales$5.12 million Price / Sales64.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book16.68Miscellaneous Outstanding Shares42,420,000Free Float24,349,000Market Cap$332.57 million OptionableOptionable Beta1.82 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Ted White (Age 59)President, CEO & Director Comp: $772.77kMr. Joe Bonaccorso (Age 60)Chief Commercial Officer Comp: $550.37kDr. Gary Goldenberg M.D. (Age 47)Chief Medical Officer Comp: $553.03kMr. P. Terence KohlerChief Financial OfficerMr. Christopher G. Hayes (Age 60)Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel Mr. Eugene ScavolaExecutive Vice President of Technical OperationsDr. Bradley J. Catalone MBAPh.D., Head of Drug DevelopmentMore ExecutivesKey CompetitorsVentyx BiosciencesNASDAQ:VTYXKamadaNASDAQ:KMDAOrganogenesisNASDAQ:ORGOCorMedixNASDAQ:CRMDNeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsSold 29,646 shares on 5/1/2024Ownership: 0.024%Perceptive Advisors LLCBought 2,060,199 shares on 2/26/2024Ownership: 16.879%Avoro Capital Advisors LLCBought 1,045,935 shares on 2/14/2024Ownership: 9.510%Perceptive Advisors LlcBought 126,116 shares on 12/28/2023Total: $892,901.28 ($7.08/share)Perceptive Advisors LlcBought 54,652 shares on 12/26/2023Total: $354,691.48 ($6.49/share)View All Insider TransactionsView All Institutional Transactions VRCA Stock Analysis - Frequently Asked Questions Should I buy or sell Verrica Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRCA shares. View VRCA analyst ratings or view top-rated stocks. What is Verrica Pharmaceuticals' stock price target for 2024? 4 equities research analysts have issued 1 year price objectives for Verrica Pharmaceuticals' stock. Their VRCA share price targets range from $8.00 to $14.00. On average, they expect the company's share price to reach $11.25 in the next year. This suggests a possible upside of 43.5% from the stock's current price. View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts. How have VRCA shares performed in 2024? Verrica Pharmaceuticals' stock was trading at $7.32 at the beginning of the year. Since then, VRCA stock has increased by 7.1% and is now trading at $7.84. View the best growth stocks for 2024 here. When is Verrica Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our VRCA earnings forecast. How can I listen to Verrica Pharmaceuticals' earnings call? Verrica Pharmaceuticals will be holding an earnings conference call on Monday, May 13th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its earnings results on Thursday, February, 29th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.01. The company earned $1.99 million during the quarter, compared to the consensus estimate of $1.10 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 1,307.47%. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS). When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Verrica Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BNP Paribas Financial Markets (0.02%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Joe Bonaccorso, John A Stalfort III, Paul B Manning, Perceptive Advisors Llc and Ted White. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRCA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe Crypto 9-5 Escape PlanCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
